X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (42685) 42685
Newsletter (515) 515
Newspaper Article (453) 453
Magazine Article (338) 338
Book Chapter (328) 328
Book / eBook (95) 95
Transcript (62) 62
Book Review (16) 16
Reference (10) 10
Trade Publication Article (9) 9
Conference Proceeding (8) 8
Web Resource (8) 8
Dissertation (7) 7
Publication (6) 6
Government Document (4) 4
Streaming Video (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (33915) 33915
male (17078) 17078
female (15796) 15796
middle aged (10892) 10892
adult (9997) 9997
animals (9089) 9089
gastroenterology & hepatology (9052) 9052
aged (8129) 8129
treatment outcome (6474) 6474
pharmacology & pharmacy (5976) 5976
gastrointestinal agents - therapeutic use (5940) 5940
gastrointestinal diseases (5398) 5398
oncology (5369) 5369
care and treatment (4400) 4400
cancer (4321) 4321
surgery (4157) 4157
analysis (3928) 3928
risk factors (3922) 3922
health aspects (3869) 3869
medicine & public health (3823) 3823
research (3524) 3524
adolescent (3043) 3043
antineoplastic agents - therapeutic use (3005) 3005
mice (2907) 2907
medicine (2900) 2900
aged, 80 and over (2808) 2808
retrospective studies (2790) 2790
therapy (2753) 2753
double-blind (2740) 2740
research article (2577) 2577
gastroenterology (2527) 2527
anti-bacterial agents - therapeutic use (2419) 2419
gastroenterology and hepatology (2410) 2410
inflammation (2329) 2329
drug therapy (2306) 2306
medicine, general & internal (2219) 2219
diagnosis (2212) 2212
patients (2209) 2209
inflammatory bowel disease (2195) 2195
management (2192) 2192
medical research (2191) 2191
young adult (2183) 2183
chemotherapy (2160) 2160
microbiota (2089) 2089
child (2078) 2078
rats (2040) 2040
tumors (2026) 2026
prospective studies (2020) 2020
multidisciplinary sciences (2017) 2017
abridged index medicus (2005) 2005
intestine (1999) 1999
gastrointestinal tract (1948) 1948
time factors (1910) 1910
gastrointestinal agents (1888) 1888
anti-inflammatory agents, non-steroidal - adverse effects (1861) 1861
studies (1841) 1841
gastrointestinal system (1823) 1823
gastrointestinal diseases - chemically induced (1813) 1813
science (1793) 1793
prognosis (1756) 1756
disease (1749) 1749
prevention (1726) 1726
inflammatory-bowel-disease (1722) 1722
anti-inflammatory agents, non-steroidal - therapeutic use (1706) 1706
immunology (1704) 1704
endoscopy (1679) 1679
clinical trials (1676) 1676
infliximab (1666) 1666
internal medicine (1635) 1635
efficacy (1609) 1609
risk (1601) 1601
proteins (1572) 1572
follow-up studies (1561) 1561
microbiology (1506) 1506
mortality (1488) 1488
bacteria (1476) 1476
drug therapy, combination (1475) 1475
review (1445) 1445
nonsteroidal antiinflammatory drugs (1426) 1426
gastrointestinal hemorrhage - etiology (1421) 1421
imatinib mesylate (1418) 1418
dose-response relationship, drug (1376) 1376
double-blind method (1371) 1371
crohns-disease (1370) 1370
medicine, experimental (1346) 1346
drugs (1324) 1324
rodents (1295) 1295
administration, oral (1270) 1270
digestive system (1261) 1261
antibiotics (1249) 1249
pediatrics (1238) 1238
probiotics (1231) 1231
antibodies, monoclonal - therapeutic use (1226) 1226
usage (1222) 1222
expression (1210) 1210
children (1209) 1209
colon (1194) 1194
crohn disease - drug therapy (1194) 1194
physiological aspects (1186) 1186
gastrointestinal diseases - drug therapy (1167) 1167
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (29) 29
Online Resources - Online (9) 9
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (6) 6
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
UofT at Mississauga - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (42056) 42056
German (545) 545
French (504) 504
Spanish (359) 359
Japanese (351) 351
Russian (315) 315
Italian (181) 181
Chinese (125) 125
Hungarian (56) 56
Korean (51) 51
Dutch (48) 48
Polish (47) 47
Portuguese (30) 30
Danish (27) 27
Hebrew (24) 24
Romanian (24) 24
Czech (21) 21
Swedish (18) 18
Ukrainian (16) 16
Finnish (14) 14
Norwegian (14) 14
Croatian (11) 11
Serbian (10) 10
Bulgarian (7) 7
Turkish (6) 6
Arabic (4) 4
Slovak (4) 4
Slovenian (2) 2
Bosnian (1) 1
Icelandic (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cochrane library, ISSN 1465-1858, 2014, Volume 2014, Issue 11, p. CD006640
Background Tranexamic acid reduces haemorrhage through its antifibrinolytic effects. In a previous version of the present review, we found that tranexamic acid... 
Injections, Intravenous | Administration, Oral | Aluminum Hydroxide | Gastrointestinal Hemorrhage | Gastroenterology & hepatology | Anti‐Ulcer Agents | Cimetidine | Endoscopy, Gastrointestinal | DUODENUM | Pharmacology | Tranexamic Acid | Ulcer (Complicated) | Magnesium Hydroxide | Randomized Controlled Trials as Topic | Antifibrinolytic Agents | Treatment | Other bowel disorders | Magnesium | Medicine General & Introductory Medical Sciences | Haemorrhage | Ulcers (gastric or duodenal) | Drug Combinations | Lansoprazole | STOMACH | Lansoprazole [therapeutic use] | MORTALITY | HEMORRHAGE | Humans | METAANALYSES | MEDICINE, GENERAL & INTERNAL | THERAPY | INHIBITION | Anti-Ulcer Agents [therapeutic use] | Cimetidine [therapeutic use] | BLOOD-TRANSFUSION | PEPTIC-ULCER | MANAGEMENT | THROMBOSIS | Aluminum Hydroxide [therapeutic use] | Tranexamic Acid [adverse effects; therapeutic use] | Magnesium [therapeutic use] | Gastrointestinal Hemorrhage [drug therapy; mortality] | Antifibrinolytic Agents [adverse effects; therapeutic use] | CONSENSUS RECOMMENDATIONS | Magnesium Hydroxide [therapeutic use] | Cimetidine - therapeutic use | Anti-Ulcer Agents - therapeutic use | Antifibrinolytic Agents - therapeutic use | Aluminum Hydroxide - therapeutic use | Antifibrinolytic Agents - adverse effects | Gastrointestinal Hemorrhage - mortality | Tranexamic Acid - therapeutic use | Tranexamic Acid - adverse effects | Magnesium - therapeutic use | Magnesium Hydroxide - therapeutic use | Gastrointestinal Hemorrhage - drug therapy | Lansoprazole - therapeutic use
Journal Article
Nature reviews. Clinical oncology, ISSN 1759-4782, 2009, Volume 6, Issue 8, pp. 465 - 477
Antiangiogenesis agents that target the VEGF/VEGF receptor pathway have become an important part of standard therapy in multiple cancer indications... 
ONCOLOGY | POSTERIOR LEUKOENCEPHALOPATHY SYNDROME | TYROSINE KINASE INHIBITOR | PHASE-II | OVARIAN-CANCER | PACLITAXEL PLUS BEVACIZUMAB | THROMBOTIC MICROANGIOPATHY | METASTATIC COLORECTAL-CANCER | RENAL-CELL CARCINOMA | ENDOTHELIAL GROWTH-FACTOR | COOPERATIVE-ONCOLOGY-GROUP | Humans | Antibodies, Monoclonal - therapeutic use | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Benzenesulfonates - adverse effects | Bevacizumab | Brain Diseases - chemically induced | Benzenesulfonates - pharmacology | Pyridines - adverse effects | Drug Interactions | Kidney Diseases - chemically induced | Pyrroles - adverse effects | Angiogenesis Inhibitors - adverse effects | Antibodies, Monoclonal - pharmacology | Risk Factors | Angiogenesis Inhibitors - pharmacology | Forecasting | Indoles - adverse effects | Indoles - therapeutic use | Cardiovascular Diseases - chemically induced | Hemorrhage - chemically induced | Vascular Endothelial Growth Factor A - physiology | Niacinamide - analogs & derivatives | Receptors, Vascular Endothelial Growth Factor - physiology | Clinical Trials as Topic - statistics & numerical data | Neoplasm Proteins - physiology | Antibodies, Monoclonal - adverse effects | Cardiovascular Diseases - therapy | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Drug Delivery Systems | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - adverse effects | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Indoles - pharmacology | Antineoplastic Agents - pharmacology | Pyrroles - therapeutic use | Wound Healing - drug effects | Pyridines - therapeutic use | Hemorrhage - therapy | Pyrroles - pharmacology | Protein Kinase Inhibitors - therapeutic use | Capillary Leak Syndrome - chemically induced | Kidney Diseases - therapy | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Gastrointestinal Diseases - chemically induced | Antimitotic agents | Complications and side effects | Care and treatment | Colorectal cancer | Physiological aspects | Development and progression | Poisoning | Antineoplastic agents | Vascular endothelial growth factor | Risk factors | Tumors | Cancer | Index Medicus
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 07/2016, Volume 2016, Issue 7, p. CD008870
Journal Article
Gastroenterology, ISSN 0016-5085, 2016, Volume 150, Issue 2, pp. 380 - 388.e4
Journal Article
Cancer, ISSN 0008-543X, 2014, Volume 120, Issue 10, pp. 1453 - 1461
Mucositis is a highly significant, and sometimes dose-limiting, toxicity of cancer therapy. The goal of this systematic review was to update the Multinational... 
no | gastrointestinal | mucositis | guidelines | oral | stomatitis | Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO) | HEAD | GASTROINTESTINAL MUCOSITIS | ISOO | CELL TRANSPLANTATION | RANDOMIZED-TRIAL | ZINC SUPPLEMENTATION | NECK-CANCER | ONCOLOGY | MUCOSAL INJURY | ORAL MUCOSITIS | DOUBLE-BLIND | LEVEL LASER THERAPY | Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC | Sucralfate - administration & dosage | Humans | Radiotherapy - adverse effects | Antineoplastic Agents - administration & dosage | Protective Agents - therapeutic use | Mucositis - prevention & control | Proctitis - prevention & control | Antineoplastic Agents - adverse effects | Anti-Inflammatory Agents - therapeutic use | Neoplasms - radiotherapy | Intercellular Signaling Peptides and Proteins - administration & dosage | Low-Level Light Therapy | Esophagitis - therapy | Analgesics - therapeutic use | Proctitis - therapy | Anti-Infective Agents - therapeutic use | Evidence-Based Medicine | Mucositis - therapy | Cytokines - administration & dosage | Esophagitis - etiology | Stomatitis - etiology | Mucositis - chemically induced | Oral Hygiene | Anti-Ulcer Agents - administration & dosage | Neoplasms - drug therapy | Phototherapy | Stomatitis - therapy | Proctitis - etiology | Mucositis - etiology | Stomatitis - chemically induced | Esophagitis - prevention & control | Radiation-Protective Agents - therapeutic use | Stomatitis - prevention & control | Amifostine - therapeutic use | Cryotherapy | Hyperbaric Oxygenation | Practice guidelines (Medicine) | Usage | Care and treatment | Mucositis | Analysis | Cancer | Index Medicus | Abridged Index Medicus | Review
Journal Article
BMC Complementary and Alternative Medicine, ISSN 1472-6882, 02/2014, Volume 14, Issue 1, p. 71
.... Present study was undertaken to validate these folkloric uses. Methods: A crude methanol extract of the aerial parts of Isodon rugosus (Ir.Cr... 
Spasmogenic activity | Traditional uses | Spasmolytic activity | Isodon rugosus | Analgesic activity | BRONCHODILATOR | LAVANDULAEFOLIA ESSENTIAL OIL | PAKISTAN | ANTICHOLINESTERASE | SMOOTH-MUSCLE | INTEGRATIVE & COMPLEMENTARY MEDICINE | CALCIUM | DISEASE | RABBIT | ACETYLCHOLINESTERASE INHIBITORS | MEDICINAL-PLANTS | Bronchodilator Agents - therapeutic use | Vasodilator Agents - therapeutic use | Plant Extracts - pharmacology | Calcium Channel Blockers - therapeutic use | Male | Trachea - drug effects | Jejunum - drug effects | Muscle, Smooth - drug effects | Antiemetics - therapeutic use | Anti-Inflammatory Agents - therapeutic use | Female | Parasympatholytics - therapeutic use | Rabbits | Vasodilator Agents - pharmacology | Isodon | Anti-Inflammatory Agents - pharmacology | Antipyretics - therapeutic use | Aorta - drug effects | Lipoxygenase Inhibitors - therapeutic use | Bronchodilator Agents - pharmacology | Antioxidants - pharmacology | Calcium Channel Blockers - pharmacology | Parasympatholytics - pharmacology | Antioxidants - therapeutic use | Ethnopharmacology | Gastrointestinal Agents - pharmacology | Animals | Cholinesterase Inhibitors - pharmacology | Muscle Contraction - drug effects | Gastrointestinal Agents - therapeutic use | Mice | Antipyretics - pharmacology | Cholinesterase Inhibitors - therapeutic use | Lipoxygenase Inhibitors - pharmacology | Plant Extracts - therapeutic use | Antiemetics - pharmacology | Usage | Methanol | Hypertension | Smooth muscle | Experiments | Asthma | Studies | Leaves | Constituents | Pain | Sodium | Analgesics | Rodents | Coronary vessels | Pharmacy | Laboratory animals | Potassium
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 06/2018, Volume 2018, Issue 6, p. CD006332
Background Opioid‐induced bowel dysfunction (OIBD) is characterised by constipation, incomplete evacuation, bloating, and gastric reflux. It is one of the... 
Quaternary Ammonium Compounds | Intestinal Diseases | Oxycodone | Receptors, Opioid, mu | Palliative Care | Palliative and supportive care | Naltrexone | Gastrointestinal | 2019 4. Palliative, supportive, frailty | Nalbuphine | Neoplasms | Randomized Controlled Trials as Topic | Narcotic Antagonists | Symptomatic relief | Naloxone | Piperidines | Child health | Opioid‐Related Disorders | Medicine General & Introductory Medical Sciences | Palliative & other supportive care | Constipation | Defecation | Gastrointestinal Agents | Cancer | Piperidines [therapeutic use] | EFFICACY | SAFETY | Humans | GUIDELINES | Gastrointestinal Agents [therapeutic use] | Intestinal Diseases [chemically induced; drug therapy] | MEDICINE, GENERAL & INTERNAL | Receptors | SUBCUTANEOUS METHYLNALTREXONE | Constipation [chemically induced; drug therapy] | PARALLEL-GROUP | Nalbuphine [therapeutic use] | mu [antagonists & inhibitors] | Naloxone [therapeutic use] | INDUCED CONSTIPATION | Opioid-Related Disorders [drug therapy] | Naltrexone [analogs & derivatives; therapeutic use] | Opioid | Quaternary Ammonium Compounds [therapeutic use] | PROLONGED-RELEASE TABLETS | Defecation [drug effects] | PAIN | Narcotic Antagonists [therapeutic use] | DOUBLE-BLIND | ADVANCED ILLNESS | Naltrexone - analogs & derivatives | Naltrexone - therapeutic use | Opioid-Related Disorders - drug therapy | Intestinal Diseases - chemically induced | Male | Neoplasms - complications | Nalbuphine - therapeutic use | Female | Constipation - drug therapy | Oxycodone - adverse effects | Oxycodone - therapeutic use | Defecation - drug effects | Quaternary Ammonium Compounds - therapeutic use | Intestinal Diseases - drug therapy | Narcotic Antagonists - adverse effects | Naloxone - therapeutic use | Receptors, Opioid, mu - antagonists & inhibitors | Constipation - chemically induced | Narcotic Antagonists - therapeutic use | Piperidines - therapeutic use | Naloxone - adverse effects | Gastrointestinal Agents - therapeutic use | Naltrexone - adverse effects
Journal Article